These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3157961)

  • 21. The origin, by mutation, of high level resistance to ceftazidime and cefotaxime in a clinical isolate of Enterobacter cloacae.
    Blahová J; Lesická-Hupková M; Králiková K; Krcméry V; Mikovicová A
    J Chemother; 1996 Aug; 8(4):266-9. PubMed ID: 8873831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A hospital outbreak of high-level beta-lactam-resistant Enterobacter spp.: association more with ampicillin and cephalosporin therapy than with nosocomial transmission.
    Walder M; Haeggman S; Tullus K; Burman LG
    Scand J Infect Dis; 1996; 28(3):293-6. PubMed ID: 8863365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of previous use of antibiotics on development of resistance to extended-spectrum cephalosporins in patients with enterobacter bacteremia.
    Lee SO; Kim YS; Kim BN; Kim MN; Woo JH; Ryu J
    Eur J Clin Microbiol Infect Dis; 2002 Aug; 21(8):577-81. PubMed ID: 12226687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outbreak of cephalosporin resistant Enterobacter cloacae infection in a neonatal intensive care unit.
    Modi N; Damjanovic V; Cooke RW
    Arch Dis Child; 1987 Feb; 62(2):148-51. PubMed ID: 3827292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of resistance types in Enterobacter cloacae 1977 and 1985.
    Søgaard P; Togsverd E; Mansa B
    Acta Pathol Microbiol Immunol Scand B; 1987 Oct; 95(5):297-302. PubMed ID: 3499749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infective endocarditis due to Enterobacter cloacae resistant to third- and fourth-generation cephalosporins.
    Yoshino Y; Okugawa S; Kimura S; Makita E; Seo K; Koga I; Matsunaga N; Kitazawa T; Ota Y
    J Microbiol Immunol Infect; 2015 Apr; 48(2):226-8. PubMed ID: 23017689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefpirome (HR 810): lack of selection of beta-lactamase overproducing variants.
    Cullmann W; Dick W
    J Antibiot (Tokyo); 1985 Jul; 38(7):912-9. PubMed ID: 3875601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of resistance to beta-lactam agents in enterobacteriaceae species with group I beta-lactamases in Spain.
    Colom K; Fernández-Aranguiz A; Alonso R; Suinaga E; Cisterna R
    Microb Drug Resist; 1996; 2(3):353-9. PubMed ID: 9158795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of KPC-2-producing Escherichia coli, Citrobacter freundii, Enterobacter cloacae, Enterobacter aerogenes, and Klebsiella oxytoca isolates from a Chinese Hospital.
    Luo Y; Yang J; Ye L; Guo L; Zhao Q; Chen R; Chen Y; Han X; Zhao J; Tian S; Han L
    Microb Drug Resist; 2014 Aug; 20(4):264-9. PubMed ID: 24433026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory activity and resistance to hydrolysis by beta-lactamases of some (D,L)-7-(alpha-fluoroacylamino)cephalosporins.
    Somma S; Malabarba A; Gastaldo L; Cavalleri B
    Farmaco Sci; 1984 May; 39(5):463-72. PubMed ID: 6376165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii.
    Deal EN; Micek ST; Ritchie DJ; Reichley RM; Dunne WM; Kollef MH
    Pharmacotherapy; 2007 Feb; 27(2):191-9. PubMed ID: 17253909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical relevance of Enterobacter infections.
    Shlaes DM
    Clin Ther; 1993; 15 Suppl A():21-8. PubMed ID: 8513457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
    Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC
    Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fluoroquinolone and aminoglycoside resistance in chromosomal cephalosporinase-overproducing gram-negative bacilli strains with inducible beta-lactamase].
    López-Yeste M; Xercavins M; Lite J; Cuchí E; Garau J
    Enferm Infecc Microbiol Clin; 1996 Apr; 14(4):211-4. PubMed ID: 9044634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Place of cefotaxime in the treatment of septicaemias due to enterobacteriaceae (author's transl)].
    Bastin R; Frottier J; Vilde JL; Bure A
    Nouv Presse Med; 1981 Feb; 10(8):598-600. PubMed ID: 6259601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae.
    Muller A; Lopez-Lozano JM; Bertrand X; Talon D
    J Antimicrob Chemother; 2004 Jul; 54(1):173-7. PubMed ID: 15150164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
    Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Use of imipenem-cilastatin in neonatal septicemias caused by gram-negative bacilli multiresistant to beta-lactam antibiotics].
    Bompard Y; Lambert T; Gantzer A; Chastel A; Voinnesson A; Aufrant C
    Pathol Biol (Paris); 1988 May; 36(5):521-4. PubMed ID: 3043351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.